Glucocorticoid osteoporosis--mechanisms and management

Department of Medicine, University of Auckland, New Zealand.

Glucocorticoids are potent osteopenic agents, producing negative calcium and bone balance via actions at many sites. The most significant adverse effects of glucocorticoid drugs on the skeleton are probably a direct inhibition of matrix synthesis by the osteoblast, reductions in calcium absorption in both the gut and the renal tubule, and the production of hypogonadism, particularly in men. Reductions in bone density of 10-40% result, the loss being more marked in trabecular bone and in patients receiving a high cumulative dose of the steroid. Fractures occur in about 30% of individuals who take these drugs for an average of 5 years. Bone loss is reversible when glucocorticoid treatment is withdrawn. Bone density can also be increased by sex hormone replacement in those with demonstrable deficiency, by bisphosphonates, and possibly by vitamin D metabolites. All patients treated with glucocorticoids for more than 6 months should be considered for bone densitometry and be offered appropriate drug treatment if values are towards the lower end of the young normal range or if there is already evidence of fractures occurring after minimal trauma. With this approach, the significant morbidity associated with steroid osteoporosis might be substantially avoided.

This article has been cited by other articles:

				M. F. Faienza, G. Brunetti, S. Colucci, L. Piacente, M. Ciccarelli, L. Giordani, G. C. Del Vecchio, M. D'Amore, L. Albanese, L. Cavallo, et al. Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Imbalance J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2269 - 2276. [Abstract] [Full Text] [PDF]

				A. Bitto, F. Polito, B. Burnett, R. Levy, V. Di Stefano, M. A. Armbruster, H. Marini, L. Minutoli, D. Altavilla, and F. Squadrito Protective effect of genistein aglycone on the development of osteonecrosis of the femoral head and secondary osteoporosis induced by methylprednisolone in rats J. Endocrinol., June 1, 2009; 201(3): 321 - 328. [Abstract] [Full Text] [PDF]

				M.-H. Kim, G.-S. Lee, E.-M. Jung, K.-C. Choi, G.-T. Oh, and E.-B. Jeung Dexamethasone differentially regulates renal and duodenal calcium-processing genes in calbindin-D9k and -D28k knockout mice Exp Physiol, January 1, 2009; 94(1): 138 - 151. [Abstract] [Full Text] [PDF]

				M. E Miller and J. G Kral Surgery for obesity in older women Menopause Int, December 1, 2008; 14(4): 155 - 162. [Abstract] [Full Text] [PDF]

				A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, J. Davidson, and I. R. Reid The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1305 - 1310. [Abstract] [Full Text] [PDF]

				J. M. Paterson, J. R. Seckl, and J. J. Mullins Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R642 - R652. [Abstract] [Full Text] [PDF]

				S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. A. Rosei, D. Valle, N. Iori, J. P Bilezikian, J. D Veldhuis, and A. Giustina Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects Eur. J. Endocrinol., February 1, 2005; 152(2): 199 - 205. [Abstract] [Full Text] [PDF]

				J. G. J. Hoenderop, B. Nilius, and R. J. M. Bindels Calcium Absorption Across Epithelia Physiol Rev, January 1, 2005; 85(1): 373 - 422. [Abstract] [Full Text] [PDF]

				J. Justesen, L. Mosekilde, M. Holmes, K. Stenderup, J. Gasser, J. J. Mullins, J. R. Seckl, and M. Kassem Mice Deficient in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Lack Bone Marrow Adipocytes, but Maintain Normal Bone Formation Endocrinology, April 1, 2004; 145(4): 1916 - 1925. [Abstract] [Full Text] [PDF]

				T. Nijenhuis, J. G.J. Hoenderop, and R. J.M. Bindels Downregulation of Ca2+ and Mg2+ Transport Proteins in the Kidney Explains Tacrolimus (FK506)-Induced Hypercalciuria and Hypomagnesemia J. Am. Soc. Nephrol., March 1, 2004; 15(3): 549 - 557. [Abstract] [Full Text] [PDF]

				P. Robson and A. Hughes Glucocorticoids in palliative medicine: is osteoporosis a problem? Palliative Medicine, October 1, 2003; 17(7): 645 - 646. [PDF]

				J. D. Ringe, A. Dorst, H. Faber, K. Ibach, and J. Preuss Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis Rheumatology, June 1, 2003; 42(6): 743 - 749. [Abstract] [Full Text] [PDF]

				M. J. Evans, K. Lai, L. J. Shaw, D. C. Harnish, and C. C. Chadwick Estrogen Receptor {alpha} Inhibits IL-1{beta} Induction of Gene Expression in the Mouse Liver Endocrinology, July 1, 2002; 143(7): 2559 - 2570. [Abstract] [Full Text] [PDF]

				G. Yosipovitch, T. S. Hoon, and G. C. Leok Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients Arch Dermatol, April 1, 2001; 137(4): 477 - 481. [Abstract] [Full Text] [PDF]

				N. Sasaki, E. Kusano, Y. Ando, K. Yano, E. Tsuda, and Y. Asano Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis Nephrol. Dial. Transplant., March 1, 2001; 16(3): 479 - 482. [Abstract] [Full Text] [PDF]

				J. A McLean, S. I Barr, and J. C Prior Cognitive dietary restraint is associated with higher urinary cortisol excretion in healthy premenopausal women Am. J. Clinical Nutrition, January 1, 2001; 73(1): 7 - 12. [Abstract] [Full Text] [PDF]

				D. L. Seidner and A. Licata Parenteral Nutrition-Associated Metabolic Bone Disease: Pathophysiology, Evaluation, and Treatment Nutr Clin Pract, August 1, 2000; 15(4): 163 - 170. [Abstract] [PDF]

				L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				G. K. Miller, M. G. Valerio, M. V. Pino, J. L. Larson, A. Viau, N. Hamelin, R. Labbe, and C. M. Banks Chronic Effects of the Novel Glucocorticosteroid RPR 106541 Administered to Beagle Dogs by Inhalation Toxicol Pathol, March 1, 2000; 28(2): 226 - 236. [Abstract] [PDF]

				F. Iqbal, J. Michaelson, L. Thaler, J. Rubin, J. Roman, and M. S. Nanes Declining Bone Mass in Men With Chronic Pulmonary Disease* : Contribution of Glucocorticoid Treatment, Body Mass Index, and Gonadal Function Chest, December 1, 1999; 116(6): 1616 - 1624. [Abstract] [Full Text] [PDF]

				L. C. Hofbauer, F. Gori, B. L. Riggs, D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, and S. Khosla Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis Endocrinology, October 1, 1999; 140(10): 4382 - 4389. [Abstract] [Full Text]

				I. R. Reid Glucocorticoid Effects on Bone J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1860 - 1862. [Full Text]

				I. Chiodini, V. Carnevale, M. Torlontano, S. Fusilli, G. Guglielmi, M. Pileri, S. Modoni, A. Di Giorgio, A. Liuzzi, S. Minisola, et al. Alterations of Bone Turnover and Bone Mass at Different Skeletal Sites due to Pure Glucocorticoid Excess: Study in Eumenorrheic Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1863 - 1867. [Abstract] [Full Text]

				S. COWAN, S. MORIN, and P. ERNST Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases Thorax, May 1, 1998; 53(5): 331 - 332. [Full Text]

				M. J. Paul-Clark, L. Mancini, P. Del Soldato, R. J. Flower, and M. Perretti Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis PNAS, February 5, 2002; 99(3): 1677 - 1682. [Abstract] [Full Text] [PDF]